Gelonghui, March 1 | Leadman (300289.SZ) said on the investor interactive platform that the company's R&D and production base has adopted high industry standards and has built a large-scale, advanced and efficient fully automated diagnostic reagent production line. The assembly line includes four parallel production lines, which fully automate the preparation, canning, labeling and packaging, and has a production capacity of 250,000 liters of in vitro biochemical diagnostic reagents and 2,500 liters of in vitro immunological diagnostic reagents. The company has successively been certified as “2018 Beijing Intelligent Manufacturing Benchmark Enterprise” and “2022 Beijing Intelligent Manufacturing Benchmarking Enterprise (Digital Workshop)”.
利德曼(300289.SZ)：研发生产基地拥有25万升体外生化诊断试剂和2500升体外免疫诊断试剂的生产能力
Leadman (300289.SZ): The R&D and production base has a production capacity of 250,000 liters of in vitro biochemical diagnostic reagents and 2,500 liters of in vitro immunodiagnostic reagents
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.